MRI of arthritis with the USPIO SH U 555 C: Optimization of T1 enhancement;MRT der arthritis mit dem USPIO SH U 555 C: Optimierung des T1-enhancements

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 178, Issue 2, 2006, Pages 200-206

  Simon, Gerhard ^a,b,c   Daldrup Link, H ^a   Von Vopelius Feldt, J ^a   Wendland, M ^a   Fu, Y ^a   Schlegel, J ^b   Rummeny, E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Box 0628 ^*  (United States)

Author keywords

Animal investigations; Arthritides; Contrast agents; MR imaging; USPIO

Indexed keywords

CONTRAST MEDIUM; SHU 555C; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HISTOPATHOLOGY; INFLAMMATION; KNEE ARTHRITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; RAT STRAIN; SYNOVITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CONTRAST MEDIA; FEMALE; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IRON; KNEE JOINT; MAGNETIC RESONANCE IMAGING; OXIDES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 32544448055     PISSN: 14389029     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858634     Document Type: Article

References (33)

1. Porth CM. Pathophysiology. Diseases of the skin and connective tissues. Philadelphia: Lippincott,1998: 2630-2634
2. Klippel J. Primer on the rheumatic diseases. Atlanta: Arthritis Foundation, 1993
3. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21: S154-S157
4. Ostendorf B, Peters R, Dann P et al. Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis. Arthritis Rheum 2001; 44: 2492-2502
5. Rand T, Imhof H, Czerny C et al. Discrimination between fluid, synovium, and cartilage in patients with rheumatoid arthritis: contrast enhanced Spin Echo versus non-contrast-enhanced fat-suppressed Gradient Echo MR imaging. Clin Radiol 1999; 54: 107-110
6. Narvaez JA, Narvaez J, Roca Y et al. MR imaging assessment of clinical problems in rheumatoid arthritis. Eur Radiol 2002; 12: 1819-1828
7. Sugimoto H, Takeda A, Masuyama J et al. Early-stage rheumatoid arthritis: diagnostic accuracy of MR imaging. Radiology 1996; 198: 185-192
8. Sugimoto H, Takeda A, Hyodoh K. MR imaging for evaluation of early rheumatoid arthritis. Semin Musculoskelet Radiol 2001; 5: 159-165
9. Sugimoto H, Takeda A, Hyodoh K. Early-stage rheumatoid arthritis: prospective study of the effectiveness of MR imaging for diagnosis. Radiology 2000; 216: 569-575
10. Tehranzadeh J, Ashikyan O, Dascalos J. Advanced imaging of early rheumatoid arthritis. Radiol Clin North Am 2004; 42: 89-107
11. McQueen FM, Stewart N, Crabbe J et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57: 350-356
12. Klarlund M, Ostergaard M, Jensen KE et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000; 59: 521-528
13. Schmitz SA. Eisenoxidverstärkte MRT inflammatorischer atherosklerotischer Läsionen: Übersichtexperimenteller und erster klinischer Ergebnisse. Fortschr Röntgenstr 2003; 175: 469-476
14. Taupitz M, Schmitz S, Hamm B. Superparamagnetische Eisenoxidpartikel: Aktueller Stand und zukünftige Entwicklungen. Fortschr Röntgenstr 2003; 175: 752-765
15. Leiner T, Ho KY, Ho VB et al. Multicenter phase-II trial of safety and efficacy of NC100150 for steady-state contrast-enhanced peripheral magnetic resonance angiography. Eur Radiol 2003; 13: 1620-1627
16. Wacker FK, Reither K, Ebert W et al. MR image-guided endovascular procedures with the ultrasmall superparamagnetic iron oxide SH U 555 C as an intravascular contrast agent: study in pigs. Radiology 2003; 226: 459-464
17. Reimer P, Bremer C, Allkemper T et al. Myocardial perfusion and MR angiography of chest with SH U 555 C: results of placebo-controlled clinical phase i study. Radiology 2004; 231: 474-481
18. Schmitz SA, Albrecht T, Jensen K et al. SPIO-unterstützte MR-Angiographie des portalvenösen Systems. Fortschr Röntgenstr 2000; 172: 51-54
19. Saini S, Sharma R, Baron RL et al. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging. Clin Radiol 2000; 55: 690-695
20. Chambon C, Clement O, Le Blanche A et al. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 1993; 11: 509-519
21. Panting JR, Taylor AM, Gatehouse PD et al. First-pass myocardial perfusion imaging and equilibrium signal changes using the intravascular contrast agent NC100150 injection. J Magn Reson Imaging 1999; 10: 404-410
22. Turetschek K, Roberts TP, Floyd E et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 2001; 13: 882-888
23. Daldrup-Link HE, Rydland J, Helbich TH et al. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology 2003; 229: 885-892
24. Beckmann N, Falk R, Zurbrugg S et al. Macrophage infiltration into the rat knee detected by MRI in a model of antigen-induced arthritis. Magn Reson Med 2003; 49: 1047-1055
25. Lutz AM, Seemayer C, Corot C et al. Detection of Synovial Macrophages in an Experimental Rabbit Model of Antigen-induced Arthritis: Ultra-small Superparamagnetic Iron Oxide-enhanced MR Imaging. Radiology 2004; 27: 27
26. Clarke SE, Weinmann HJ, Dai E et al. Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits. Radiology 2000; 214: 787-794
27. Hallas B, Lehman S, Bosak A et al. Establishment of behavioral parameters for the evaluation of osteopathic treatment principles in a rat model of arthritis. J Am Osteopath Assoc 1997; 97: 207-214
28. Tombach B, Reimer P, Mahler M et al. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: Phase 1 clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad Radiol 2002; 9: S425-427
29. Tanimoto A, Oshio K, Suematsu M et al. Relaxation effects of clustered particles. J Magn Reson Imaging 2001; 14: 72-77
30. Weissleder R, Elizondo G, Wittenberg J et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175: 489-493
31. Kaim AH, Jundt G, Wischer T et al. Functional-morphologic MR imaging with ultrasmall superparamagnetic particles of iron oxide in acute and chronic soft-tissue infection: study in rats. Radiology 2003; 227: 169-174
32. Kaim AH, Wischer T, O'Reilly T et al. MR imaging with ultrasmall superparamagnetic iron oxide particles in experimental soft-tissue infections in rats. Radiology 2002; 225: 808-814
33. Hudgins PA, Anzai Y, Morris MR et al. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study. AJNR Am J Neuroradiol 2002; 23: 649-656